Skip to main content

Pharmaceutical R&D powered by Global Business Services

Re-Imagining operational R&D through GBS


With the average cost to develop a new drug rapidly increasing, there is a significant opportunity for pharmaceutical organisations to leverage Global Business Services (GBS) to act as a strategic transformation asset.

This report highlights key areas of opportunity across the R&D organisation that could be delivered from a GBS model. Additionally, it highlights key considerations for leaders to keep in mind as they embark on this journey including:

  • A hyper-focus on patient experience
  • Driving innovation with focused partnership models
  • How to leverage the scale of GBS and harness its global talent pool

Did you find this useful?

Thanks for your feedback

If you would like to help improve further, please complete a 3-minute survey